Jazz Pharmaceuticals plc

NASDAQ:JAZZ   2:07:37 PM EDT
109.35
+3.23 (+3.04%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)6.62B
Current PE13.72
Forward PE 22.14
2yr Forward PE 5.07
See more stats
Estimates Current Quarter
Revenue$1.05 Billion
Adjusted EPS-$7.42
See more estimates
10-Day MA$107.87
50-Day MA$108.61
200-Day MA$117.97
See more pivots

Jazz Pharmaceuticals plc Stock, NASDAQ:JAZZ

Waterloo Exchange, Waterloo Road, Dublin, Dublin 4
Ireland
Phone: +353.1.634.7800
Number of Employees: 2800

Description

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.